NovaBridge Biosciences American Depositary Shares (NBP)

• Market cap: $170M
• 1 day: -1.34%
• 5 days: -8.7%
• 1 month: -19.23%
• 3 months: -49.31%
• 6 months: -63.88%
• Year to date: -65.57%
• 1 year: -41.67%
• 5 years: -97.91%
• 10 years: -88.24%
• Sector: Healthcare
• Industry: Biotechnology

About: NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.

Employees: 30